Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a report issued on Tuesday morning, Zacks.com reports.

Quince Therapeutics Stock Up 4.1 %

Quince Therapeutics stock opened at $0.85 on Tuesday. The stock has a market cap of $36.73 million, a PE ratio of -1.12 and a beta of 0.86. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.15 and a current ratio of 6.15. Quince Therapeutics has a one year low of $0.51 and a one year high of $1.43. The stock has a fifty day moving average of $0.72 and a 200 day moving average of $0.79.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter.

Insider Activity at Quince Therapeutics

In other news, CEO Dirk Thye acquired 77,500 shares of Quince Therapeutics stock in a transaction that occurred on Thursday, August 29th. The stock was bought at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the transaction, the chief executive officer now owns 766,941 shares in the company, valued at $529,189.29. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, President Charles S. Ryan purchased 48,387 shares of Quince Therapeutics stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the transaction, the president now directly owns 122,461 shares in the company, valued at $79,599.65. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Dirk Thye purchased 77,500 shares of Quince Therapeutics stock in a transaction on Thursday, August 29th. The stock was bought at an average price of $0.69 per share, with a total value of $53,475.00. Following the transaction, the chief executive officer now owns 766,941 shares of the company’s stock, valued at approximately $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 158,887 shares of company stock worth $105,609. 16.80% of the stock is owned by insiders.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.